SV Health Investors’ Dementia Discovery Fund Announces $269m Final Close of DDF-2

Packaging Compliance Labs Completes Acquisition of Quest Engineering Solutions, Expands Testing Capabilities and East Coast Presence

SUN Behavioral Health Acquires Seaside’s Community Agencies, Expanding Access to Community-Based Mental Health Services Across the Southeast

Centauri Health Solutions Acquires MedAllies, Broadens Health Data Network to Support Mission Critical Use Cases
British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2

Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment

2024 SV Therapeutics Impact & ESG Report
Read More

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise

Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More

SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics

SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner

Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership

Merck to Acquire Caraway Therapeutics, Inc.

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 7 October 2024Portfolio NewsNitrase Therapeutics Presents Preclinical Data Demonstrating Antibody Prevents Spread of Pathology of Parkinson’s Disease at SfN’s Neuroscience 2024 Scientific Congress
- 18 September 2024SV NewsNavigating the $100B+ Alzheimer's Market | Laurence Barker, Partner at The Dementia Discovery Fund - SV Health Investors
- 10 September 2024Portfolio NewsQurAlis Doses First Participant Cohort in Phase 1 Multiple-Ascending Dose (MAD) Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
- 9 September 2024SV NewsEyes on the target: Drug discovery’s new paradigm
- 9 September 2024SV NewsNeurology’s human data revolution
- 4 September 2024Portfolio NewsHarness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director
- 3 September 2024Portfolio NewsAmphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
- 24 July 2024Portfolio NewsTransposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia
- 12 July 2024SV NewsUK needs Covid-style push on dementia drugs, says ex-head of vaccine taskforce
- 2 July 2024Portfolio NewsASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center
- 10 June 2024SV NewsMission-Driven Dementia Funding with DDF's Jonathan Behr
- 3 June 2024Portfolio NewsQurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD